Your session is about to expire
← Back to Search
Monoclonal Antibodies
Taltz for Laryngostenosis
Phase 2
Waitlist Available
Led By Nwanmegha Young, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
diagnosis of idiopathic subglottic stenosis
Diagnosis of idiopathic subglottic stenosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 weeks from baseline, up to 24 months
Awards & highlights
Study Summary
This trial is testing whether a drug that inhibits IL-17A activation can reduce scarring in the voice box, potentially eliminating the need for surgery.
Who is the study for?
This trial is for individuals with idiopathic subglottic stenosis, a narrowing of the airway below the vocal cords. Participants must consent to study procedures and be available throughout the study. It excludes those with tuberculosis history, pregnant or lactating women, people with inflammatory bowel disease, or allergies to Taltz.Check my eligibility
What is being tested?
The trial tests if Taltz can inhibit IL-17A activation to reduce scar tissue growth in patients' airways, potentially decreasing the need for repeated surgeries.See study design
What are the potential side effects?
Taltz may cause side effects such as injection site reactions (like redness), increased risk of infections due to immune system suppression, and possibly allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with idiopathic subglottic stenosis.
Select...
I have been diagnosed with idiopathic subglottic stenosis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 8 weeks from baseline, up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 weeks from baseline, up to 24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Airway, Dyspnea, Voice, and Swallowing (ADVS) Summary Assessment
Chronic Obstructive Airway Disease
Change in European Quality of Life-Five Dimensions (EQ-5D) Questionnaire
+6 moreSide effects data
From 2019 Phase 4 trial • 566 Patients • NCT0315155113%
Nasopharyngitis
6%
Upper respiratory tract infection
6%
Injection site reaction
1%
Menometrorrhagia
1%
Pyrexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ixekizumab
Adalimumab
Ixekizumab Follow-up
Adalimumab Follow-up
Trial Design
1Treatment groups
Experimental Treatment
Group I: TalzExperimental Treatment1 Intervention
All participants receive Talz
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,737,653 Total Patients Enrolled
Lilly PharmaceuticalCompanyUNKNOWN
Nwanmegha Young, MDPrincipal InvestigatorYale University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My condition affects my vocal cords.I have a history of inflammatory bowel disease.I have been diagnosed with idiopathic subglottic stenosis.I am willing and able to follow the study's procedures and be available for its duration.I have been diagnosed with idiopathic subglottic stenosis.I have had tuberculosis in the past.
Research Study Groups:
This trial has the following groups:- Group 1: Talz
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this clinical experiment currently enrolling participants?
"The most recent updates on clinicaltrials.gov state that patient recruitment for this trial is not occurring at the moment, although it was initially posted in November 2022 and last edited in July 2021. However, there are presently 218 other trials actively seeking out candidates."
Answered by AI
Is Taltz a safe pharmaceutical treatment for individuals to utilize?
"As there is evidence of safety but not efficacy for this Phase 2 trial, Taltz was rated as a '2' on our team's scale."
Answered by AI
Who else is applying?
What state do they live in?
Connecticut
California
Other
Florida
How old are they?
65+
18 - 65
What site did they apply to?
Yale New Haven Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Why did patients apply to this trial?
My growth keeps coming back. Took 4 years to get diagnosed and over last 12 month had 9 procedures. Its completely taken control of my life.
PatientReceived no prior treatments
Share this study with friends
Copy Link
Messenger